A shooting combination for flu and COVID-19 using antibodies generated by messenger RNA in a study, but United States Government Regulators want to see data on whether the new vaccine protects people from getting sick.
Modern vaccine manufacturer researchers reported in a study published on Wednesday that the new combined shot generated a stronger immune response against COVID-19 and most flu strains than existing independent shots in people over 50 years. Side effects were injection, fatigue and headaches pain. Modern previously reported a summary of the results of the company sponsored by the company in 8,000 people.
RNM technology is used in approval COVID-19 and RSV Shots, but it has not yet been approved for a flu vaccine. Modern believes that RNM could accelerate the production of flu vaccines compared to traditional processes that use chicken eggs or giant cell deposits. A combined photo could also improve vaccination rates, investigators wrote in the study published in the Journal of the American Medical Association.
Dr. Greg Pole, who studies the response to the vaccine in May Clinic and did not participate in the new study, said he is not convinced that a combined shot would be popular. And although the flu comes in seasonal waves, COVID-19 has spread throughout the year, said Poland, raising challenges on how to have the shots to maintain strong protection.
He would also like to see data about how well the new shot protected people from infection and hospitalization.
The findings are based on the measurement of antibodies in the blood of the participants after 29 days, an indication of short -term disease protection.
Last week, Modern promoted its objective date for the approval of the vaccine at 2026 after the Food and Medicines Administration requested a more direct measure: how much it reduced the risk of disease.
“I agree in this case with the FDA that the efficacy data is important to see,” said Poland.
The Secretary of Health, Robert F. Kennedy Jr., has questioned the safety of RNM vaccines, but the president of Modern, Stephen Hoge, told investors in a profit call last week that the conversations with the FDA were productive and “businesses as always.”
Also last week, Novavax said The FDA was asking the company to execute a new clinical trial of its COVID-19 protein-based vaccine after the agency grants full approval, sowing uncertainty over other vaccine updates.
___
The Department of Health and Sciences of Associated Press receives support from the Science and Educational Media Group of the Howard Hughes Medical Institute and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
